Stifel reiterates Heartflow stock rating on clinical data strength

Heartflow reported Q4 FY2025 revenue of $49.1M (+40% YoY) and EPS of -$0.12 versus a -$0.15 forecast, and TTM revenue reached $176M (+40%) with a 77% gross margin though still unprofitable. Management reiterated confidence in a 2026 plaque revenue ramp and the underpenetrated U.S. CCTA market, while Stifel maintained a Buy/$40 PT, Piper Sandler reiterated Overweight with a $38 PT, and Canaccord raised its PT to $43. These beats and bullish analyst actions underpin positive sentiment and near-term upside for the stock despite continued unprofitability.

Analysis

Heartflow sits at the intersection of faster CCTA adoption and cloud/software-driven clinical workflows; that structural shift reallocates margin from capital-equipment vendors to analytics providers that can embed into radiology/cardiology workflows and recurring-revenue models. Second-order beneficiaries include high-throughput outpatient imaging centers and contrast-media suppliers as procedure volumes rise, while legacy cath‑lab device vendors face gradual elective-case erosion as non‑invasive triage improves.

The biggest near-term gating items are commercial: payor coverage, hospital capital cycles, and integration into EMR/PACS—each operates on multi‑quarter to multi‑year timelines and can flip revenue trajectories quickly. Regulatory or IP enforcement outcomes are binary catalysts that could materially reprice the opportunity in weeks; conversely, a marquee IDN win or broad payor policy change would accelerate penetration and validate recurring revenue modeling.

Valuation sensitivity is high: upside is concentrated in successful scale of per‑study or subscription monetization and margin expansion from software automation, while downside comes from pricing compression if scanner OEMs bundle analytics. Monitoring unit economics (revenue per study, gross margin per study) and contract structure (transactional vs subscription) will tell whether revenue growth translates to durable free cash flow.

Consensus appears to price steady execution but underweights execution risk from long sales cycles and competitive bundling; it may also underappreciate the multi-year acceleration scenario if payors adopt dedicated reimbursement for plaque analytics, which would convert a clinical advantage into durable TAM capture. Both outcomes create asymmetric returns—binary negative legal/regulatory shocks vs outsized long‑term market share gains if adoption inflects.

Key Decisions for Investors

• Core long HTFL (12–18 month horizon): scale into a 6–8% position on pullbacks or soft guidance releases, target 40–60% upside if IDN wins/payor coverage accelerate, set stop-loss at ~30% below entry to limit runway risk tied to commercial execution.
• Leveraged call exposure (18‑month LEAPs): buy HTFL 25–35% OTM calls to capture upside from adoption inflection with defined premium loss; objective 3:1 reward:risk if annualized revenue per study and margins expand per guidance.
• Pair trade (12 months): long HTFL / short ABT or BSX (equal dollar weight) to express non‑invasive triage displacement of elective coronary device volumes; expect divergence if CCTA adoption rises materially—risk that acute/interventional demand remains stable, hedge with 15% collars.
• Downside protection: if owning HTFL outright, buy 6‑month puts (10–15% OTM) to cap a single‑quarter commercial miss; alternatively implement a collar to reduce net premium while limiting downside to ~15–20% over the next two reporting cycles.